Regulus Therapeutics Inc. News Releases http://ir.regulusrx.com/ Regulus Therapeutics Inc. News Releases en Regulus Therapeutics Reports First Quarter 2019 Financial Results and Recent Updates http://ir.regulusrx.com/news-releases/news-release-details/regulus-therapeutics-reports-first-quarter-2019-financial Closing of First Tranche of $41.8 Million Private Placement of Equity Term Loan Restructured Providing Up to Two Years of Interest Only and Extended Maturity Date to May 2022 Engagement with FDA on RGLS4326 Clinical Program Ongoing LA JOLLA, Calif. , May 9, 2019 /PRNewswire/ -- Regulus Therapeutics Thu, 09 May 2019 16:05:00 -0400 Regulus Therapeutics Inc. News Releases 11896 Regulus Therapeutics Announces Closing of First Tranche of $41.8 Million Private Placement of Equity http://ir.regulusrx.com/news-releases/news-release-details/regulus-therapeutics-announces-closing-first-tranche-418-million LA JOLLA, Calif. , May 7, 2019 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the closing of the first tranche of its previously announced private placement Tue, 07 May 2019 16:05:00 -0400 Regulus Therapeutics Inc. News Releases 11871 Regulus Therapeutics Announces Restructuring of Term Loan http://ir.regulusrx.com/news-releases/news-release-details/regulus-therapeutics-announces-restructuring-term-loan Term Loan Amended to Provide Up to Two Years of Interest Only Payments and Extension of Maturity Date to May 2022 LA JOLLA, Calif. , May 6, 2019 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines Mon, 06 May 2019 09:15:00 -0400 Regulus Therapeutics Inc. News Releases 11866 Regulus Therapeutics Announces Private Placement of Equity http://ir.regulusrx.com/news-releases/news-release-details/regulus-therapeutics-announces-private-placement-equity Up to $41.8 Million in Gross Proceeds to be Funded in Two Tranches LA JOLLA, Calif. , May 6, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has Mon, 06 May 2019 09:00:00 -0400 Regulus Therapeutics Inc. News Releases 11861 Regulus to Present Preclinical Efficacy Data Highlighting Potential of Novel Treatment for Nonalcoholic Steatohepatitis at The International Liver Congress™ 2019 http://ir.regulusrx.com/news-releases/news-release-details/regulus-present-preclinical-efficacy-data-highlighting-potential Favorable Pharmacological Properties Exhibited in Preclinical Models of NASH LA JOLLA, Calif. , April 8, 2019 /PRNewswire/ --  Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced Mon, 08 Apr 2019 08:00:00 -0400 Regulus Therapeutics Inc. News Releases 11841 Regulus Reports Fourth Quarter and Year-End 2018 Financial Results and Recent Updates http://ir.regulusrx.com/news-releases/news-release-details/regulus-reports-fourth-quarter-and-year-end-2018-financial LA JOLLA, Calif. , March 18, 2019 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and year ended December 31, 2018 Mon, 18 Mar 2019 08:00:00 -0400 Regulus Therapeutics Inc. News Releases 11806 Regulus Announces Transition of Research Leadership http://ir.regulusrx.com/news-releases/news-release-details/regulus-announces-transition-research-leadership LA JOLLA, Calif. , March 15, 2019 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the resignation of Dr. Timothy Wright , Chief Research and Development Fri, 15 Mar 2019 18:00:00 -0400 Regulus Therapeutics Inc. News Releases 11801 Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme http://ir.regulusrx.com/news-releases/news-release-details/regulus-announces-clinical-candidate-nomination-treatment LA JOLLA, Calif. , Jan. 7, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the nomination of RGLS5579 as a clinical candidate for the treatment of Mon, 07 Jan 2019 08:00:00 -0500 Regulus Therapeutics Inc. News Releases 11741 Regulus Announces Preliminary Results of Planned Interim Data Analysis of RGLS4326 in New Mouse Chronic Toxicity Study http://ir.regulusrx.com/news-releases/news-release-details/regulus-announces-preliminary-results-planned-interim-data No Adverse or Other Significant Findings to Date Across All Dose Groups Tested Data Package to Be Submitted to FDA to Support Potential Resumption of Phase 1 Clinical Study LA JOLLA, Calif. , Jan. 4, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused Fri, 04 Jan 2019 16:05:00 -0500 Regulus Therapeutics Inc. News Releases 11731 Regulus Presents Preclinical Survival Data Highlighting Potential of Novel Treatment for Glioblastoma Multiforme http://ir.regulusrx.com/news-releases/news-release-details/regulus-presents-preclinical-survival-data-highlighting Single Dose of Lead anti-miR-10b Compound in Combination with temozolomide Resulted in over 150% Increase in Median Survival LA JOLLA, Calif. , Nov. 19, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company focused on the discovery and development of Mon, 19 Nov 2018 08:00:00 -0500 Regulus Therapeutics Inc. News Releases 11676